LPL and hereditary disease: The first AAV1-based drug, Alipogene tiparvovec, or GlyberaTM, was approved by the EMA to treat LPLD, a rare monogenic genetic disorder characterized by accumulation of triglycerides in plasma due to mutations in LPL. GlyberaTM carrying correct copies of LPL was developed by UniQure Inc., and widely heralded as the “the first gene therapy” in the Western world (Figure 3).